Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line

3 weeks ago 19

Jonathan Ponciano, The Motley Fool

Sun, December 28, 2025 astatine 2:31 PM CST 5 min read

Boston-based Eventide Asset Management sold 114,922 shares of Mirum Pharmaceuticals during the 3rd quarter.
Despite the sale, the wide worth of the presumption accrued by astir $50.70 cardinal from the erstwhile play acknowledgment to a staggering banal terms surge.
As of September 30, the money reported holding 2.52 cardinal MIRM shares valued astatine astir $184.92 million, making it the fund's second-largest holding.
These 10 stocks could mint the adjacent question of millionaires ›

On November 14, Boston-based Eventide Asset Management disclosed successful a U.S. Securities and Exchange Commission filing that it sold 114,922 shares of Mirum (NASDAQ:MIRM). Nevertheless, the nett presumption worth really accrued by astir $50.70 million.

According to an SEC filing dated November 14, Eventide Asset Management, LLC reduced its involvement successful Mirum (NASDAQ:MIRM) by selling 114,922 shares since the erstwhile quarter. The determination brought the fund’s presumption to 2.52 cardinal shares, oregon $184.92 million, arsenic of September 30.

Eventide sold shares, bringing Mirum to 3.04% of AUM and making it the fund’s second-largest equity holding. The presumption was antecedently astir 2.4% of the fund's AUM arsenic of the anterior quarter.

Top holdings aft the filing:

NASDAQ:GH: $207.51 cardinal (3.4% of AUM)
NASDAQ:MIRM: $184.92 cardinal (3.0% of AUM)
NASDAQ:XMTR: $169.87 cardinal (2.8% of AUM)
NYSE:TT: $168.00 cardinal (2.8% of AUM)
NASDAQ:INSM: $144.74 cardinal (2.4% of AUM)

As of Friday, shares of Mirum were priced astatine $79.26, up a staggering 89% implicit the past twelvemonth and good outperforming the S&P 500, which is alternatively up astir 15%.

Metric

Value

Price (as of Friday)	$79.26
Market Capitalization	$4.10 billion
Revenue (TTM)	$471.79 million
Net Income (TTM)	($41.42 million)

Mirum's cardinal products see LIVMARLI, an investigational oral therapy for uncommon liver diseases, and Volixibat, targeting further uncommon hepatic conditions.
The institution generates gross chiefly done the improvement and commercialization of caller therapies for uncommon and orphan diseases, focusing connected proprietary pharmaceutical products.
Primary customers are healthcare providers and institutions treating patients with uncommon cholestatic liver diseases, including those with Alagille syndrome and progressive familial intrahepatic cholestasis.

Mirum is simply a biopharmaceutical institution specializing successful therapies for debilitating uncommon and orphan diseases, with a absorption connected liver disorders. The institution leverages its expertise successful cause improvement to code important unmet aesculapian needs, driving maturation done proprietary merchandise commercialization. Its strategical accent connected uncommon illness markets provides a competitory borderline by targeting high-value, underserved diligent populations.